IRIS
INNAO, Vanessa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.453
NA - Nord America 1.311
AS - Asia 462
AF - Africa 3
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.234
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.306
IE - Irlanda 422
SE - Svezia 349
IT - Italia 308
CN - Cina 197
PL - Polonia 195
SG - Singapore 176
HU - Ungheria 59
VN - Vietnam 27
DE - Germania 24
IN - India 20
FI - Finlandia 19
BE - Belgio 17
ID - Indonesia 16
FR - Francia 12
NL - Olanda 10
GB - Regno Unito 9
PK - Pakistan 6
UA - Ucraina 6
AT - Austria 5
KR - Corea 5
RU - Federazione Russa 5
TW - Taiwan 5
HK - Hong Kong 4
MX - Messico 4
CZ - Repubblica Ceca 3
ES - Italia 3
JP - Giappone 3
RO - Romania 3
CL - Cile 2
EU - Europa 2
LT - Lituania 2
ZA - Sudafrica 2
AL - Albania 1
BR - Brasile 1
CA - Canada 1
DK - Danimarca 1
IR - Iran 1
SA - Arabia Saudita 1
TN - Tunisia 1
TR - Turchia 1
Totale 3.234
Salva come PNG Salva come JPEG
Città #
Dublin 422
Chandler 384
Nyköping 228
Warsaw 194
Messina 146
Singapore 135
Princeton 76
Ashburn 71
Medford 64
Ann Arbor 63
Beijing 59
Budapest 59
Des Moines 47
Jacksonville 42
Dearborn 40
Dong Ket 25
Los Angeles 19
Boardman 18
Cambridge 18
Wilmington 18
Brussels 17
Jakarta 16
Jinan 16
Woodbridge 16
New York 14
Nanjing 13
Rome 13
Pune 12
Tianjin 12
Bremen 11
Hangzhou 10
Hebei 10
Milan 9
Houston 8
Ningbo 8
San Mateo 8
Seattle 7
Shenyang 7
Zhengzhou 7
Redwood City 6
Bengaluru 5
Fuzhou 5
Haikou 5
Helsinki 5
Lanzhou 5
Munich 5
Strasbourg 5
Vienna 5
Falls Church 4
Latina 4
Palermo 4
Tappahannock 4
Turin 4
Catania 3
Esher 3
Gangdong-gu 3
Hong Kong 3
Jiaxing 3
Lahore 3
Madrid 3
Nanchang 3
Norwalk 3
Sector 3 3
Taizhou 3
Aci Catena 2
Bari 2
Bitonto 2
Brno 2
Cape Town 2
Cesano Maderno 2
Cordenons 2
Crosia 2
Frankfurt am Main 2
Guangzhou 2
Hiroshima 2
Ho Chi Minh City 2
Jining 2
Lurano 2
Modica 2
Monteriggioni 2
Monterrey 2
Paris 2
Paternò 2
Pescara 2
Piazza Armerina 2
Prospect 2
Qingdao 2
Rawalpindi 2
Santa Clara 2
Santo Stefano di Camastra 2
Sassari 2
Teramo 2
Tucson 2
Vignola 2
Washington 2
Albignasego 1
Auburn Hills 1
Augusta 1
Bhubaneswar 1
Brooklyn 1
Totale 2.508
Salva come PNG Salva come JPEG
Nome #
Altered Microrna Expression Profile in the peripheral Lymphomonocytes of Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 150
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 113
The cancer stem cell hypothesis: a guide to potential molecular targets. 92
Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies 89
Role of the microbiota in hematologic malignancies. 86
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient. 81
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw 81
Efficacia della chemioterapia convenzionale ad alte dosi in un caso di mieloma multiplo IgM primitivamente doppio-refrattario ai nuovi farmaci 80
SIRT1 and SIRT2 Expression correlates with advanced disease and bone lesions in Multiple Myeloma 79
Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies 76
Telomerase and telomere biology in hematological diseases: A new therapeutic target 75
Extramedullary plasmacytoma of the maxilla simulating a maxillary radicular cyst: Quick diagnosis and management 74
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma 72
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patiets’ Characteristics 70
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study 69
Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network 68
A rare spinal localization of gray zone lymphoma without mediastinal involvement: A case report and review of literature 67
IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS 67
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 66
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells 64
Vaccination of multiple myeloma: Current strategies and future prospects 64
Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. 63
Vaccination strategies in lymphoproliferative disorders: Failures and successes 58
A multivariate analysis of Multiple Myeloma subtype plasma cells 57
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 55
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 53
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma 51
Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 51
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis 50
The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention 50
Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients 49
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects 49
The metabolomic signature of hematologic malignancies 46
Feasibility, Tolerability and Efficacy of Carfilzomib, Lenalidomide and Desamethasone (KRD) in Relapsed Refractory Myeloma Patients: A Real-Life Survey of the Sicilian Myeloma Network 46
New insights into yes-associated protein signaling pathways in hematological malignancies: Diagnostic and therapeutic challenges 46
Standardisation of minimal residual disease in multiple myeloma 45
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 45
Mitochondria-targeted antioxidant SkQ1 for gammopathy-related corneal damage 45
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 44
Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. 44
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma 43
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules 43
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 41
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review) 41
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies 40
A rare pancreatic pseudoaneurysm in patient with acute pancreatitis and multiple myeloma 39
The ST2/interleukin-33 axis in hematologic malignancies: The IL-33 paradox 38
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies 37
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology 36
Nanobodies and Cancer: Current Status and New Perspectives 35
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 34
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma 34
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age 32
Reviewing the significance of vitamin d substitution in monoclonal gammopathies 30
Immune thrombocytopenia: options and new perspectives 29
Therapeutic potential of antagomiRs in haematological and oncological neoplasms 28
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma 25
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease 23
New orally active proteasome inhibitors in multiple myeloma. 21
Relationship between mitofusin 2 and cancer. 20
Radioprotective agents and enhancers factors. Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignancies 20
null 19
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma 19
New frontiers about the role of human microbiota in immunotherapy: The immune checkpoint inhibitors and CAR T-cell therapy era 19
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. 18
Oncolytic viruses and hematological malignancies: A new class of immunotherapy drugs 18
Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma 16
Immune checkpoint inhibitors in multiple myeloma: A review of the literature 7
Totale 3.435
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.766
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.766
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020186 0 0 0 0 8 44 12 2 8 57 42 13
2020/2021651 66 51 101 36 76 29 48 38 61 89 14 42
2021/2022486 4 25 8 22 14 11 27 19 22 96 39 199
2022/20231.278 119 135 65 120 65 123 9 70 505 11 35 21
2023/2024335 22 75 28 26 29 62 2 20 1 17 7 46
2024/2025313 83 32 21 89 88 0 0 0 0 0 0 0
Totale 3.435